BB
ALNY icon

BB Biotech’s Alnylam Pharmaceuticals ALNY Stock Holding History

BB Biotech’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$152M Buy
1,631,089
+59,700
+4% +$4.99M 3.83% 9
2018
Q4 		$115M Buy
1,571,389
+200,851
+15% +$15.4M 3.67% 11
2018
Q3 		$120M Buy
1,370,538
+230,000
+20% +$23.1M 3.17% 12
2018
Q2 		$112M Buy
1,140,538
+129,200
+13% +$12.8M 3.24% 13
2018
Q1 		$120M Sell
1,011,338
-40,000
-4% -$5.16M 3.33% 13
2017
Q4 		$134M Sell
1,051,338
-60,000
-5% -$7.54M 3.76% 13
2017
Q3 		$131M Sell
1,111,338
-110,000
-9% -$9.39M 3.61% 11
2017
Q2 		$97.4M Sell
1,221,338
-20,000
-2% -$1.28M 2.98% 12
2017
Q1 		$63.6M Buy
1,241,338
+50,000
+4% +$2.31M 2.08% 14
2016
Q4 		$44.6M Hold
1,191,338
– – 1.65% 14
2016
Q3 		$80.7M Hold
1,191,338
– – 2.84% 13
2016
Q2 		$66.1M Hold
1,191,338
– – 2.61% 13
2016
Q1 		$74.8M Buy
1,191,338
+58,839
+5% +$3.91M 2.97% 11
2015
Q4 		$107M Hold
1,132,499
– – 3% 13
2015
Q3 		$91M Buy
1,132,499
+167,000
+17% +$18.6M 2.89% 13
2015
Q2 		$116M Buy
965,499
+130,000
+16% +$15.5M 3.14% 13
2015
Q1 		$87.2M Buy
835,499
+84,211
+11% +$8.53M 2.6% 16
2014
Q4 		$72.9M Sell
751,288
-30,000
-4% -$2.78M 2.36% 15
2014
Q3 		$61M Buy
781,288
+160,000
+26% +$10.3M 2.48% 13
2014
Q2 		$39.2M Buy
621,288
+150,000
+32% +$8.92M 1.86% 13
2014
Q1 		$31.6M Hold
471,288
– – 1.63% 16
2013
Q4 		$30.3M Hold
471,288
– – 1.62% 14
2013
Q3 		$30.2M Buy
471,288
+16,488
+4% +$822K 1.64% 17
2013
Q2 		$14.1M Buy
+454,800
New +$12.1M 1.02% 16

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BB Biotech's ALNY Position: Q1 2019 in Review

BB Biotech increased its Alnylam Pharmaceuticals (ALNY) stake by 3.8% in Q1 2019, buying an estimated $4.99M and bringing the position to 1,631,089 shares worth $152M. The position accounts for 3.83% of the portfolio, ranked #9.

BB Biotech first reported a position in ALNY in Q2 2013 and has held it in 24 quarters since. 291 funds tracked by Wall St. Rank hold ALNY as of Q1 2019.

  • BB Biotech held 1,631,089 shares of Alnylam Pharmaceuticals worth $152M as of Q1 2019.
  • BB Biotech bought 59,700 Alnylam Pharmaceuticals shares in Q1 2019, an estimated $4.99M.
  • Alnylam Pharmaceuticals made up 3.83% of BB Biotech's portfolio in Q1 2019, its #9 holding.
  • BB Biotech first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • 291 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.